471 related articles for article (PubMed ID: 33109233)
1. Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial.
Di Cosimo S; Porcu L; Agbor-Tarh D; Cinieri S; Franzoi MA; De Santis MC; Saura C; Huober J; Fumagalli D; Izquierdo M; Piccart M; Daidone MG; de Azambuja E
Breast Cancer Res; 2020 Oct; 22(1):115. PubMed ID: 33109233
[TBL] [Abstract][Full Text] [Related]
2. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
de Azambuja E; Holmes AP; Piccart-Gebhart M; Holmes E; Di Cosimo S; Swaby RF; Untch M; Jackisch C; Lang I; Smith I; Boyle F; Xu B; Barrios CH; Perez EA; Azim HA; Kim SB; Kuemmel S; Huang CS; Vuylsteke P; Hsieh RK; Gorbunova V; Eniu A; Dreosti L; Tavartkiladze N; Gelber RD; Eidtmann H; Baselga J
Lancet Oncol; 2014 Sep; 15(10):1137-46. PubMed ID: 25130998
[TBL] [Abstract][Full Text] [Related]
3. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
[TBL] [Abstract][Full Text] [Related]
4. Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.
Huober J; Holmes E; Baselga J; de Azambuja E; Untch M; Fumagalli D; Sarp S; Lang I; Smith I; Boyle F; Xu B; Lecocq C; Wildiers H; Jouannaud C; Hackman J; Dasappa L; Ciruelos E; Toral Pena JC; Adamchuk H; Hickish T; de la Pena L; Jackisch C; Gelber RD; Piccart-Gebhart M; Di Cosimo S
Eur J Cancer; 2019 Sep; 118():169-177. PubMed ID: 31377477
[TBL] [Abstract][Full Text] [Related]
5. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
6. Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer.
Martel S; Poletto E; Ferreira AR; Lambertini M; Sottotetti F; Bertolini I; Montemurro F; Bernardo A; Risi E; Zanardi E; Ziliani S; Mura S; Dellepiane C; Del Mastro L; Minisini AM; Puglisi F
Breast; 2018 Feb; 37():142-147. PubMed ID: 29161652
[TBL] [Abstract][Full Text] [Related]
7. Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials.
Fernandez-Martinez A; Rediti M; Tang G; Pascual T; Hoadley KA; Venet D; Rashid NU; Spears PA; Islam MN; El-Abed S; Bliss J; Lambertini M; Di Cosimo S; Huobe J; Goerlitz D; Hu R; Lucas PC; Swain SM; Sotiriou C; Perou CM; Carey LA
JAMA Oncol; 2024 May; 10(5):603-611. PubMed ID: 38546612
[TBL] [Abstract][Full Text] [Related]
8. Proliferation Determined by Ki-67 Defines Different Pathologic Response to Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer.
Sánchez-Muñoz A; Navarro-Perez V; Plata-Fernández Y; Santonja A; Moreno I; Ribelles N; Alba E
Clin Breast Cancer; 2015 Oct; 15(5):343-7. PubMed ID: 25752727
[TBL] [Abstract][Full Text] [Related]
9. Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials.
Guarneri V; Griguolo G; Miglietta F; Conte PF; Dieci MV; Girardi F
ESMO Open; 2022 Apr; 7(2):100433. PubMed ID: 35276440
[TBL] [Abstract][Full Text] [Related]
10. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
[TBL] [Abstract][Full Text] [Related]
11. Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.
Solinas C; Ceppi M; Lambertini M; Scartozzi M; Buisseret L; Garaud S; Fumagalli D; de Azambuja E; Salgado R; Sotiriou C; Willard-Gallo K; Ignatiadis M
Cancer Treat Rev; 2017 Jun; 57():8-15. PubMed ID: 28525810
[TBL] [Abstract][Full Text] [Related]
12. Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab.
Ligorio F; Di Cosimo S; Verderio P; Ciniselli CM; Pizzamiglio S; Castagnoli L; Dugo M; Galbardi B; Salgado R; Loi S; Michiels S; Triulzi T; Tagliabue E; El-Abed S; Izquierdo M; de Azambuja E; Nuciforo P; Huober J; Moscetti L; Janni W; Coccia-Portugal MA; Corsetto PA; Belfiore A; Lorenzini D; Daidone MG; Vingiani A; Gianni L; Pupa SM; Bianchini G; Pruneri G; Vernieri C
J Natl Cancer Inst; 2022 Dec; 114(12):1720-1727. PubMed ID: 35789270
[TBL] [Abstract][Full Text] [Related]
13. Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.
Nuciforo PG; Aura C; Holmes E; Prudkin L; Jimenez J; Martinez P; Ameels H; de la Peña L; Ellis C; Eidtmann H; Piccart-Gebhart MJ; Scaltriti M; Baselga J
Ann Oncol; 2015 Jul; 26(7):1494-500. PubMed ID: 25851628
[TBL] [Abstract][Full Text] [Related]
14. A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).
Patel TA; Ensor JE; Creamer SL; Boone T; Rodriguez AA; Niravath PA; Darcourt JG; Meisel JL; Li X; Zhao J; Kuhn JG; Rosato RR; Qian W; Belcheva A; Schwartz MR; Kaklamani VG; Chang JC
Breast Cancer Res; 2019 Sep; 21(1):100. PubMed ID: 31477168
[TBL] [Abstract][Full Text] [Related]
15. Impact of body mass index on pathological response after neoadjuvant chemotherapy: results from the I-SPY 2 trial.
Wang H; Yee D; Potter D; Jewett P; Yau C; Beckwith H; Watson A; O'Grady N; Wilson A; Brain S; Pohlmann P; ; Blaes A
Breast Cancer Res Treat; 2024 Apr; 204(3):589-597. PubMed ID: 38216819
[TBL] [Abstract][Full Text] [Related]
16. Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).
Untch M; von Minckwitz G; Gerber B; Schem C; Rezai M; Fasching PA; Tesch H; Eggemann H; Hanusch C; Huober J; Solbach C; Jackisch C; Kunz G; Blohmer JU; Hauschild M; Fehm T; Nekljudova V; Loibl S;
J Clin Oncol; 2018 May; 36(13):1308-1316. PubMed ID: 29543566
[TBL] [Abstract][Full Text] [Related]
17. Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.
Carey LA; Berry DA; Cirrincione CT; Barry WT; Pitcher BN; Harris LN; Ollila DW; Krop IE; Henry NL; Weckstein DJ; Anders CK; Singh B; Hoadley KA; Iglesia M; Cheang MC; Perou CM; Winer EP; Hudis CA
J Clin Oncol; 2016 Feb; 34(6):542-9. PubMed ID: 26527775
[TBL] [Abstract][Full Text] [Related]
18. A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade.
Nuciforo P; Pascual T; Cortés J; Llombart-Cussac A; Fasani R; Paré L; Oliveira M; Galvan P; Martínez N; Bermejo B; Vidal M; Pernas S; López R; Muñoz M; Garau I; Manso L; Alarcón J; Martínez E; Rodrik-Outmezguine V; Brase JC; Villagrasa P; Prat A; Holgado E
Ann Oncol; 2018 Jan; 29(1):170-177. PubMed ID: 29045543
[TBL] [Abstract][Full Text] [Related]
19. Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial.
Powles RL; Redmond D; Sotiriou C; Loi S; Fumagalli D; Nuciforo P; Harbeck N; de Azambuja E; Sarp S; Di Cosimo S; Huober J; Baselga J; Piccart-Gebhart M; Elemento O; Pusztai L; Hatzis C
JAMA Oncol; 2018 Nov; 4(11):e181564. PubMed ID: 29902299
[TBL] [Abstract][Full Text] [Related]
20. Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials.
Fontanella C; Lederer B; Gade S; Vanoppen M; Blohmer JU; Costa SD; Denkert C; Eidtmann H; Gerber B; Hanusch C; Hilfrich J; Huober J; Schneeweiss A; Paepke S; Jackisch C; Mehta K; Nekljudova V; Untch M; Neven P; von Minckwitz G; Loibl S
Breast Cancer Res Treat; 2015 Feb; 150(1):127-39. PubMed ID: 25677740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
